Immunohistochemical evaluation of two antibodies against PD-L1 and prognostic significance of PD-L1 expression in epithelioid peritoneal malignant mesothelioma: A RENAPE study.

[1]  S. Msika,et al.  The RENAPE observational registry: rationale and framework of the rare peritoneal tumors French patient registry , 2017, Orphanet Journal of Rare Diseases.

[2]  S. Steinberg,et al.  Malignant Mesothelioma Effusions Are Infiltrated by CD3+ T Cells Highly Expressing PD‐L1 and the PD‐L1+ Tumor Cells within These Effusions Are Susceptible to ADCC by the Anti–PD‐L1 Antibody Avelumab , 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[3]  S. Msika,et al.  Diffuse malignant peritoneal mesothelioma: Evaluation of systemic chemotherapy with comprehensive treatment through the RENAPE Database: Multi-Institutional Retrospective Study. , 2016, European journal of cancer.

[4]  J. Lunceford,et al.  Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial. , 2016, The Lancet. Oncology.

[5]  N. Le Stang,et al.  Immune biomarkers PD-1/PD-L1 and TLR3 in malignant pleural mesotheliomas. , 2016, Human pathology.

[6]  M. Deraco,et al.  The Role of Ki-67 and Pre-cytoreduction Parameters in Selecting Diffuse Malignant Peritoneal Mesothelioma (DMPM) Patients for Cytoreductive Surgery (CRS) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) , 2016, Annals of Surgical Oncology.

[7]  Drew M. Pardoll,et al.  PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma. , 2016, The New England journal of medicine.

[8]  F. Galateau-Sallé,et al.  New Markers for Separating Benign From Malignant Mesothelial Proliferations: Are We There Yet? , 2016, Archives of pathology & laboratory medicine.

[9]  A. Krasinskas,et al.  Prognostic significance of morphological growth patterns and mitotic index of epithelioid malignant peritoneal mesothelioma , 2016, Histopathology.

[10]  K. Steele,et al.  Safety and antitumour activity of durvalumab plus tremelimumab in non-small cell lung cancer: a multicentre, phase 1b study. , 2016, The Lancet. Oncology.

[11]  F. Galateau-Sallé,et al.  The 2015 World Health Organization Classification of Tumors of the Pleura: Advances since the 2004 Classification. , 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[12]  A. Borczuk,et al.  Programmed Death Ligand-1 Immunohistochemistry--A New Challenge for Pathologists: A Perspective From Members of the Pulmonary Pathology Society. , 2016, Archives of pathology & laboratory medicine.

[13]  G. Rossi,et al.  BAP1 (BRCA1-associated protein 1) is a highly specific marker for differentiating mesothelioma from reactive mesothelial proliferations , 2015, Modern Pathology.

[14]  M. Berry,et al.  Impact of mesothelioma histologic subtype on outcomes in the Surveillance, Epidemiology, and End Results database. , 2015, The Journal of surgical research.

[15]  J. Lunceford,et al.  Pembrolizumab for the treatment of non-small-cell lung cancer. , 2015, The New England journal of medicine.

[16]  E. Felip,et al.  Analysis of Expression of Programmed Cell Death 1 Ligand 1 (PD-L1) in Malignant Pleural Mesothelioma (MPM) , 2015, PloS one.

[17]  H. Kohrt,et al.  Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients , 2014, Nature.

[18]  Antoni Ribas,et al.  Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial , 2014, The Lancet.

[19]  Antoni Ribas,et al.  Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. , 2013, The New England journal of medicine.

[20]  A. Gown,et al.  Guidelines for pathologic diagnosis of malignant mesothelioma: 2012 update of the consensus statement from the International Mesothelioma Interest Group. , 2013, Archives of pathology & laboratory medicine.

[21]  C. Drake,et al.  Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. , 2012, The New England journal of medicine.

[22]  David C. Smith,et al.  Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. , 2012, The New England journal of medicine.

[23]  G. Alí,et al.  Tryptase Mast Cells in Malignant Pleural Mesothelioma as an Independent Favorable Prognostic Factor , 2009, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[24]  J. Testa,et al.  Mesothelioma Epidemiology, Carcinogenesis, and Pathogenesis , 2008, Current treatment options in oncology.

[25]  G. Freeman,et al.  PD-1 and its ligands in tolerance and immunity. , 2008, Annual review of immunology.

[26]  P. Boffetta.  Epidemiology of peritoneal mesothelioma: a review. , 2007, Annals of oncology : official journal of the European Society for Medical Oncology.

[27]  E. Brun,et al.  Prognostic significance of histomorphologic parameters in diffuse malignant peritoneal mesothelioma. , 2006, Archives of pathology & laboratory medicine.

[28]  P. Sugarbaker,et al.  Comprehensive management of diffuse malignant peritoneal mesothelioma. , 2006, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[29]  J. Esquivel,et al.  Prospective Morbidity and Mortality Assessment of Cytoreductive Surgery Plus Perioperative Intraperitoneal Chemotherapy To Treat Peritoneal Dissemination of Appendiceal Mucinous Malignancy , 2006, Annals of Surgical Oncology.

[30]  A. Krasinskas,et al.  The prognostic significance of BAP1, NF2, and CDKN2A in malignant peritoneal mesothelioma , 2016, Modern Pathology.

[31]  W. Travis.  WHO classification of tumours of the lung, pleura, thymus and heart , 2015 .